Swedbank AB Sells 214,996 Shares of Abbott Laboratories $ABT

Key Points

• Swedbank AB cut its Abbott position by 15%, selling 214,996 shares and leaving it with 1,220,317 shares (about 0.07% of the company) valued at approximately $152.9 million.
• Abbott beat quarterly estimates with $1.15 EPS (vs. $1.14 expected) and $11.16 billion revenue (vs. $10.99 billion), and set FY2026 guidance of $5.38–$5.58 EPS and Q2 guidance of $1.25–$1.31.
• The company announced a quarterly dividend of $0.63 ($2.52 annualized, ~2.9% yield), and Director Daniel J. Starks bought 10,000 shares at $92.65, modestly increasing his stake.

Swedbank AB cut its position in Abbott Laboratories (NYSE:ABT - Free Report) by 15.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,220,317 shares of the healthcare product maker's stock after selling 214,996 shares during the quarter. Swedbank AB owned approximately 0.07% of Abbott Laboratories worth $152,894,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ABT. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares during the period. United Bank lifted its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $87.18 on Wednesday. The business's fifty day moving average is $103.83 and its two-hundred day moving average is $115.68. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $151.84 billion, a P/E ratio of 24.42, a P/E/G ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 52 week low of $86.16 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.9%. Abbott Laboratories's payout ratio is currently 70.59%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Argus reduced their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating for the company in a research report on Friday, April 17th. Finally, Evercore reduced their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $119.43.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company's stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 in the last three months. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.